DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183030

Effect of tamsulosin on blood glucose levels in euglycemic and alloxan induced diabetic rats and its interaction with glibenclamide

Sumit Satpute, Rajan Nerurkar, Manish Kokne

Abstract


Background: To evaluate the effect of tamsulosin on blood glucose levels in euglycaemic rats and to investigate the effect of glibenclamide, tamsulosin and their combination on alloxan induced diabetic rats.

Methods: Albino male wistar rats were randomly assigned into 6 groups (2 euglycaemic and 4 alloxan induced diabetic rats groups). In Euglycaemic rats either normal saline (0.5ml P.O) or tamsulosin (0.072mg/kg P.O) were given and blood glucose levels was estimated at 0 hr, 30min, 1hr, 2hr, 4hr on day 1 and at 0hr and 1hr on day 3 and day 7. Four groups of diabetic rats were given normal saline (0.5ml P.O), glibenclamide (5mg/kg P.O), tamsulosin (0.072mg/kg P.O), combination of glibenclamide and tamsulosin respectively and blood glucose levels were estimated on day 1, 3 and 7. Repeated measures ANOVA or paired ‘t ‘test were used for within group comparison and one way ANOVA or unpaired ‘t’ test were used for between group comparison.

Results: In euglycaemic rats tamsulosin caused significant rise in blood glucose levels at 1 hr on all days and in diabetic rats tamsulosin itself did not cause any significant alteration in blood glucose levels. However, its combination with glibenclamide delayed the onset of hypoglycemic effect of glibenclamide & also reduced its hypoglycemic effect.

Conclusions: Tamsulosin significantly increase blood glucose level in euglycaemic rats and it interact with Glibenclamide to reduce its hypoglycemic activity in diabetic rats.


Keywords


Alloxan induced diabetic rats, Glibenclamide, Tamsulosin

Full Text:

PDF

References


Manjunath S, Santosh N. Kugali, Priyadarshani M. Deodurg. Effect of clonidine on glucose level in euglycemic and alloxan-induced diabetic rats and its interaction with glibenclamide. Ind J Pharmacol ,2010;41(5):218-20.

Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(7):2562-8.

Brady PA, Terzic A, The sulfonylurea controversy: more question from the heart. J Am Coll Cardiol. 1998;31(5):950-6.

Zanten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104(1):1-9.

Denis L, McConnell J, Yoshida O. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, et al, eds. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia, Plymouth, UK: Health Publication Ltd; 1998:669-683.

Borgsteede S, Bruggeman R, Hoefnagel R. Tamsulosin and hyperglycaemia in patients with diabetes. J Med of Netherl. 2010;68(3):141-3.

Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol. 2005;45(6):599-604.

Inukai T, Inukai Y, Matsutomo R, Okumura K, Takanashi K, Takebayashi K, et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004;32(2):206-13.

Faintrenie G, Geloen A. α1 adrenergic stimulation of glucose uptake in rat white adipocytes. J Pharmacol Exp Ther. 1998;286(2):607-10.

Martin III WH, Tolley TK, Saffitz JE. Autoradiographic delineation of skeletal muscle α1-adrenergic receptor distribution. Am J Physiol. 1990;259:H1402-H1408.

Rokosh DG, Bailey BA, Stewart AF. Distribution of α1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with α1B and α1D. Biochem Biophys Res Commun. 1994;200:1177-84.

Rattigan S, Appleby GJ, Edwards SJ, McKinstry WJ. α-adrenergic receptors in rat skeletal muscle. Biochem Biophys Res Commun. 1986;136:1071-7.

Zhong H, Minneman KP. α1-Adrenoceptor subtypes. Eur J Pharmacol. 1999;375:261-76.

Cheng JT, Liu IM, Yen ST, Chen PC. Role of α1A-adrenoceptor in the regulation of glucose uptake into white adipocyte of rats in vitro. Auton Neurosci. 2000;84(3):140-6.

Doenst T, Taegtmeyer H. α-Adrenergic stimulation mediates glucose uptake through phosphatidylinositol 3-kinase in rat heart. Circ Res. 1999;84:467-74.

Boschmann M, Krupp G. In vivo response to α1-adrenoreceptor stimulation in human white adipose tissue. Obes Res. 2002;10(6):555-8.

Flechtner-Mors M, Jenkinson CP, Alt A, Biesalski HK, Adler G, Ditschuneit HH. Sympathetic regulation of glucose uptake by the α1-adrenoceptor in human obesity. Obes Res. 2004;2(4):612-20.

Aileen JFK. Review: The use of animal models in diabetes research. Brit Jour of Phar. 2012;166:877-94.

Onyije FM, Avwioro OG. Effect of Ethanolic Extract of Bauhinia Monandra Leaf on the Liver of Alloxan Induced Diabetic Rats. J Phys Pharm Adv. 2012;2(1):59-63.

Martha S. Pancreatic Hormones and Antidiabetic Drugs. In: Katzung BG, Masters SB, Trevor AJ (eds.) Basic and clinical pharmacology. 11th Edi. New Delhi: Tata McGraw Hill education private limited; 2010:727-752.